

## Atezolizumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion	<div style="border: 1px solid #0070C0; border-radius: 5px; padding: 5px; margin-bottom: 10px;">             Other specified malignant neoplasms of bronchus or lung           </div> Therapeutic equivalent to <a href="#">pembrolizumab</a> for <div style="border: 1px solid #0070C0; border-radius: 5px; padding: 5px; margin-top: 10px;">             Other specified malignant neoplasms of bronchus or lung           </div>

## Cemiplimab

Section	Indications
Immunomodulators	Therapeutic equivalent to <a href="#">pembrolizumab</a> for <div style="border: 1px solid #0070C0; border-radius: 5px; padding: 5px; margin-top: 10px;">             Other specified malignant neoplasms of bronchus or lung           </div>

## Daratumumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL	<div style="border: 1px solid #0070C0; border-radius: 5px; padding: 5px; margin-top: 10px;">             Plasma cell myeloma           </div>

## Durvalumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 120 mg per 2.4 mL in vial; 500 mg per 10 mL in vial	<div style="border: 1px solid #0070C0; border-radius: 5px; padding: 5px; margin-top: 10px;">             Other specified malignant neoplasms of bronchus or lung           </div>

## Filgrastim

Section	Indications
Immunomodulators Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial	<div style="border: 1px solid #0070C0; border-radius: 5px; padding: 5px; margin-top: 10px;">             Acquired neutropaenia           </div>

## Lenalidomide

Section	Indications
Immunomodulators Oral > Solid: 25 mg	<div style="border: 1px solid #0070C0; border-radius: 5px; padding: 5px; margin-top: 10px;">             Plasma cell myeloma           </div>

## Nivolumab

### Section

Immunomodulators

Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion

### Indications

Other specified malignant neoplasms of bronchus or lung

Melanoma of skin

## Pegfilgrastim

### Section

Immunomodulators

Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

### Indications

Acquired neutropaenia

## Pembrolizumab

### Section

Immunomodulators

Parenteral > General injections > IV: 50 mg powder for injection

### Indications

Therapeutic equivalent to nivolumab for

Melanoma of skin

Other specified malignant neoplasms of bronchus or lung

## Thalidomide

### Section

Immunomodulators

Oral > Solid: 50 mg

### Indications

Plasma cell myeloma

## Tislelizumab

### Section

Immunomodulators

Parenteral > General injections > IV: 100 mg per 10 mL

### Indications

Malignant neoplasms of urinary tract

Hodgkin lymphoma

Other specified malignant neoplasms of bronchus or lung

## Toripalimab

### Section

Immunomodulators

Parenteral > General injections > IV: 240 mg per 6 mL in vial

### Indications

Malignant neoplasms of nasopharynx

Malignant neoplasms of oesophagus